Disease-related and drug-induced changes in dopamine transporter expression might undermine the reliability of imaging studies of disease progression in Parkinson's disease

Parkinsonism and Related Disorders

Volumn 11, Issue 8, 2005, Pages 475-484

  Winogrodzka, A ^a,b   Booij, J ^a,c   Wolters, E Ch ^a,b  

^a School of Neurosciences Amsterdam   (Netherlands)

^b VU UNIVERSITY MEDICAL CENTER   (Netherlands)

^c ACADEMIC MEDICAL CENTER   (Netherlands)

Author keywords

Dopamine transporter (DAT); Parkinson's disease; Positron emission tomography (PET); Single photon emission computed tomography (SPECT)

Indexed keywords

[2 [[2 [[[3 (4 CHLOROPHENYL) 8 METHYL 8 AZABICYCLO[3.2.1]OCT 2 YL]METHYL](2 MERCAPTOETHYL)AMINO]ETHYL]AMINO]ETHANETHIOLATO]OXOTECHNETIUM TC 99M; AMANTADINE; AMFEBUTAMONE; AMPHETAMINE; ANTIDEPRESSANT AGENT; APOMORPHINE; BROMOCRIPTINE; CARBIDOPA PLUS LEVODOPA; COCAINE; DOPAMINE; DOPAMINE 2 RECEPTOR STIMULATING AGENT; DOPAMINE RECEPTOR STIMULATING AGENT; DOPAMINE TRANSPORTER; FLUVOXAMINE; HALOPERIDOL; LEVODOPA; METHYLPHENIDATE; NEUROLEPTIC AGENT; NEUROPROTECTIVE AGENT; OLANZAPINE; PERGOLIDE; PRAMIPEXOLE; QUINPIROLE; RADIOLIGAND; RESERPINE; RISPERIDONE; SELEGILINE; SEROTONIN UPTAKE INHIBITOR; TRACER; UNINDEXED DRUG;

BRAIN SCINTISCANNING; CLINICAL TRIAL; COMPARATIVE STUDY; DEGENERATIVE DISEASE; DIAGNOSTIC IMAGING; DISEASE COURSE; DOPAMINERGIC NERVE CELL; DOPAMINERGIC SYSTEM; DRUG EFFECT; DRUG PROTEIN BINDING; DRUG SCREENING; HIGH RISK POPULATION; HUMAN; LONG TERM CARE; NERVE CELL DEGENERATION; NERVOUS SYSTEM FUNCTION; NONHUMAN; PALLIATIVE THERAPY; PARKINSON DISEASE; POSITRON; PRIORITY JOURNAL; PROTEIN EXPRESSION; RELIABILITY; REVIEW; SINGLE PHOTON EMISSION COMPUTER TOMOGRAPHY; TREATMENT FAILURE;

ANIMALS; ANTIPARKINSON AGENTS; DISEASE PROGRESSION; DOPAMINE PLASMA MEMBRANE TRANSPORT PROTEINS; HUMANS; PARKINSON DISEASE; REPRODUCIBILITY OF RESULTS; TOMOGRAPHY, EMISSION-COMPUTED, SINGLE-PHOTON;

EID: 27744471383     PISSN: 13538020     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.parkreldis.2005.08.001     Document Type: Review

References (74)

1. H. Braak, K. Del Tredici, U. Rub, R.A. de Vos, E.N. Jansen Steur, and E. Braak Staging of brain pathology related to sporadic Parkinson's disease Neurobiol Aging 24 2003 197 211
2. G. Tissingh, J. Booij, P. Bergmans, A. Winogrodzka, A.G.M. Janssen, E.A. van Royen, J.C. Stoof, and E.C. Wolters Iodine-123-N-ω-fluoropropyl- 2β-carbomethoxy-3β-(4-iodophenyl)tropane SPECT in healthy controls and early-stage, drug-naive Parkinson's disease J Nucl Med 39 1998 1143 1148
3. G. Tissingh, P. Bergmans, J. Booij, A. Winogrodzka, E.A. van Royen, J.C. Stoof, and E.C. Wolters Drug-naive patients with Parkinson's disease in Hoehn and Yahr stages I and II show a bilateral decrease in striatal dopamine transporters by [123I]β-CIT SPECT J Neurol 245 1998 14 20
4. B.M. Ravina, S.C. Fagan, R.G. Hart, C.A. Hovinga, D.D. Murphy, T.M. Dawson, and J.R. Marler Neuroprotective agents for clinical trials in Parkinson's disease: a systematic assessment Neurology 22 2003 1234 1240
5. B.J. Ciliax, C. Heilman, L.L. Demchyshyn, Z.B. Pristupa, E. Ince, S.M. Hersch, H.B. Niznik, and A.I. Levey The dopamine transporter: immunochemical characterization and localization in brain J Neurosci 15 1995 1714 1723
6. J.P. Seibyl, K.L. Marek, D. Quinlan, K. Sheff, S. Zoghbi, Y. Zea-Ponce, R.M. Baldwin, B. Fussell, E.O. Smith, and D.S. Charney Decreased single-photon emission computed tomographic [123I]β-CIT striatal uptake correlates with symptom severity in Parkinson's disease Ann Neurol 38 1995 589 598
7. 123I]FP-CIT SPECT shows a pronounced decline of striatal dopamine transporter labelling in early and advanced Parkinson's disease J Neurol Neurosurg Psychiatry 62 1997 133 140
8. W. Pirker Correlation of dopamine transporter imaging with parkinsonian motor handicap: how close is it? Mov Disord 18 Suppl. 7 2003 S43 S51
9. J.J. Frost, A.J. Rosier, S.G. Reich, J.S. Smith, M.D. Ehlers, S.H. Snyder, H.T. Ravert, and R.F. Dannals Positron emission tomographic imaging of dopamine transporter with 11C-WIN 35,428 reveals marked declines in mild Parkinson's disease Ann Neurol 34 1993 423 431
10. H.W. Berendse, J. Booij, C.M.J.E. Francot, P.L. Bergmans, R. Hijman, J.C. Stoof, and E.C. Wolters Subclinical dopaminergic dysfunction in asymptomatic Parkinson's disease patients' relatives with a decreased sense of smell Ann Neurol 50 2001 34 41
11. E.Ch. Wolters, C. Francot, P. Bergmans, A. Winogrodzka, J. Booij, H.W. Berendse, and J.C. Stoof Preclinical (premotor) Parkinson's disease J Neurol 247 Suppl. II 2000 103 109
12. P.K. Morrish Brain imaging to assess the effects of dopamine agonists on progression of Parkinson's disease JAMA 288 2002 312 313
13. P.K. Morrisk Is it time to abandon functional imaging in the study of neuroprotection? Mov Disord 17 2002 229 232
14. B. Ravina, D. Eidelberg, J.E. Ahlskog, R.L. Albin, D.J. Brooks, M. Carbon, V. Dhawan, A. Feigin, S. Fahn, M. Guttman, K. Gwinn-Hardy, H. McFarland, R. Innis, R.G. Katz, K. Kieburtz, S.J. Kish, N. Lange, J.W. Langston, K. Marek, L. Morin, D. Murphy, W.H. Oertel, G. Oliver, Y. Palesch, W. Powers, J. Seibyl, K.D. Sethi, C.W. Shults, P. Sheehy, A.J. Stoessl, and R. Holloway The role of radiotracer imaging in Parkinson's disease Neurology 64 2005 208 215
15. D. Stoffers, H.W. Berendse, J.B. Deijen, and E.C. Wolters Motor perseveration is an early sign of Parkinson's disease Neurology 57 2001 2111 2113
16. S. Hocherman, and N. Giladi Visuomotor control abnormalities in patients with unilateral parkinsonism Neurology 50 1998 1648 1654
17. E.B. Montgomery Jr, K.B. Baker, K. Lyons, and W.C. Koller Abnormal performance on the PD test battery by asymptomatic first degree relatives Neurology 52 1999 757 762
18. G. Tissingh, H.W. Berendse, P. Bergmans, R. De Waard, B. Drukarch, J.C. Stoof, and E.C. Wolters Loss of olfaction in de novo and treated Parkinson's disease: possible implications for early diagnosis Mov Disord 16 2001 41 46
19. 123I]beta-CIT/SPECT imaging demonstrates bilateral loss of dopamine transporters in hemi-Parkinson's disease Neurology 46 1996 231 237
20. 123I-PE2I SPECT Neuroimage 19 2003 810 816
21. K. Stiasny-Kolster, Y. Doerr, J.C. Moller, H. Hoffken, T.M. Behr, W.H. Oertel, and G. Mayer Combination of 'idiopathic' REM sleep behaviour disorder and olfactory dysfunction as possible indicator for alpha-synucleinopathy demonstrated by dopamine transporter FP-CIT-SPECT Brain 128 2005 126 137
22. M.M. Ponsen, D. Stoffers, J. Booij, B.L.F. van Eck-Smit, E.C. Wolters, and H.W. Berendse Idiopathic hyposmia as a preclinical sign of Parkinson's disease Ann Neurol 56 2004 173 181
23. S. Fahn, and R.L. Elton Members of the unified Parkinson's disease rating scale development committee. Unified Parkinson's disease rating scale S. Fahn C.D. Marsden D.B. Calne M. Goldstein Recent developments in Parkinson's disease vol. 2 1987 Macmillan Healthcare Information Florham Park, NY 153 164
24. J. Fearnley, and A. Lees Ageing and Parkinson's disease: substantia nigra regional selectivity Brain 114 1991 2283 2301
25. H. Bernheimer, W. Birkmayer, O. Hornykiewicz, K. Jellinger, and F. Seitelberger Brain dopamine and the syndromes of parkinsonism and Huntington. Clinical, morphological and neurochemical correlations J Neurol Sci 20 1973 415 455
26. 123I]β- CIT SPECT J Neural Transm 107 2000 543 552
27. 18F]CFT Ann Neurol 47 2000 804 808
28. K. Marek, R. Innis, C. van Dyck, B. Fussell, M. Early, S. Eberly, D. Oakes, and J. Seibyl [123I]beta-CIT SPECT imaging assessment of the rate of Parkinson's disease progression Neurology 57 2001 2089 2094
29. A. Winogrodzka, P. Bergmans, J. Booij, E.A. van Royen, A.G. Janssen, and E.C. Wolters [123I]FP-CIT SPECT is a useful method to monitor the rate of dopaminergic degeneration in early-stage Parkinson's disease J Neural Transm 108 2001 1011 1019
30. M. Chouker, K. Tatsch, R. Linke, O. Pogarell, K. Hahn, and J. Schwarz Striatal dopamine transporter binding in early to moderately advanced Parkinson's disease: monitoring of disease progression over 2 years Nucl Med Commun 22 2001 721 725
31. W. Pirker, S. Djamshidian, S. Asenbaum, W. Gerschlager, G. Tribl, M. Hoffmann, and T. Brucke Progression of dopaminergic degeneration in Parkinson's diesease and atypical parkinsonism: a longitudinal β-CIT SPECT study Mov Disord 17 2002 45 53
32. W. Pirker, I. Holler, W. Gerschlager, S. Asenbaum, G. Zettinig, and T. Brucke Measuring the rate of progression of Parkinson's disease over a 5-year period with β-CIT SPECT Mov Disord 18 2003 1266 1272
33. 123I]beta-CIT SPECT is a useful method for monitoring dopaminergic degeneration in early stage Parkinson's disease J Neurol Neurosurg Psychiatry 74 2003 294 298
34. 18F]CFT PET Synapse 48 2003 109 115
35. 18F]dopa-PET and clinical study of the rate of progression in Parkinson's disease Brain 119 1996 585 591
36. 18F]dopa-PET J Neurol Neurosurg Psychiatry 64 1998 314 319
37. Parkinson Study Group Dopamine transporter brain imaging to assess the effects of pramipexole vs levodopa on Parkinson disease progression JAMA 287 2002 1653 1661
38. M. Ida, I. Miyazaki, K. Tanaka, H. Kabuto, E. Iwata-Ichikawa, and N. Ogawa Dopamine D2 receptor-mediated antioxidant and neuroprotective effects of ropinirole, a dopamine agonist Brain Res 838 1999 51 59
39. C.W. Olanow, P. Jener, and D.J. Brooks Doapmine agonists and neuroprotection in Parkinson's disease C.W. Olanow P. Jener Neuroprotection in Parkinson's disease 1998 Wells Medical Limited Royal Tunbridge Wells 331 344
40. M. Tanaka, A. Sotomatsu, H. Kanai, and S. Hirai Dopa and dopamine cause cultured neuronal death in the presence of iron J Neurosci 101 1991 198 203
41. A.L. Whone, R.L. Watts, A.J. Stoessl, M. Davis, S. Reske, C. Nahmias, A.E. Lang, O. Rascol, M.J. Ribeiro, P. Remy, W.H. Poewe, R.A. Hauser, D.J. Brooks, and REAL-PET Study Group REAL-PET Study Group. Slower progression of Parkinson's disease with ropinirole versus levodopa: the REAL-PET study Ann Neurol 54 2003 93 101
42. W.H. Oertel, J. Schwartz, K.L. Leenders, H.P. Hundemer, A. Lledo, and E.C. Wolters Results of a three year randomized, double-blind PET-controlled study of pergolide vs. l-dopa as monotherapy in early Parkinson's disease (PELMOPET-trial) J Neurol Sci 187 Suppl. 1 2001 444
43. The Parkinson Study Group Levodopa and the progression of Parkinson's disease N Engl J Med 51 2498 2004 2508
44. H.E. Melikian, and K.M. Buckley Membrane trafficking regulates the activity of the human dopamine transporter J Neurosci 19 1999 7699 7710
45. J.M. Gulley, S. Doolen, and N.R. Zahniser Brief, repeated exposure to substrates down-regulates dopamine transporter function in Xenopus oocytes in vitro and rat dorsal striatum in vivo J Neurochem 83 2002 400 411
46. E. Rebas, L. Lachowicz, and A. Lachowicz Estradiol modulates the synapsis phosphorylation by various protein kinases in the rat brain under in vitro and in vivo conditions J Physiol Pharmacol 56 2005 39 48
47. C.H. van Dyck, J.P. Seibyl, R.T. Malison, M. Laruelle, E. Wallace, S.S. Zoghbi, Y. Zea-Ponce, R.M. Baldwin, D.S. Charney, and P.B. Hoffer Age-related decline in striatal dopamine transporter binding with iodine-123-beta-CIT SPECT J Nucl Med 36 1995 1175 1181
48. 123I]FP-CIT SPECT in healthy volunteers Eur J Nucl Med 27 2000 867 869
49. M.J. Zigmond, E.D. Abercrombie, T.W. Berger, A.A. Grace, and E.M. Stricker Compensations after lesions of central dopaminergic neurons: some clinical and basic implications Trends Neurosci 13 1990 290 296
50. M.K. Stachowiak, R.W. Keller Jr, E.M. Stricker, and M.J. Zigmond Increased dopamine efflux from striatal slices during development and after nigrostriatal bundle damage J Neurosci 7 1987 1648 1654
51. G.L. Snyder, R.W. Keller Jr, and M.J. Zigmond Dopamine efflux from striatal slices after intracerebral 6-hydroxydopamine: evidence for compensatory hyperactivity of residual terminals J Pharmacol Exp Ther 253 1990 867 876
52. C.S. Lee, A. Samii, V. Sossi, T.J. Ruth, M. Schulzer, J.E. Holden, J. Wudel, P.K. Pal, R. de la Fuente-Fernandez, D.B. Calne, and A.J. Stoessl In vivo positron emission tomographic evidence for compensatory changes in presynaptic dopaminergic nerve terminals in Parkinson's disease Ann Neurol 47 2000 493 503
53. 123]beta-CIT: pharmacological characterization of brain uptake in nonhuman primates Synapse 13 1993 295 309
54. F. Thibaut, J.J. Bonet, J.M. Vaugeois, and J. Constentin Pharmacological modifications of dopamine transmission do not influence the striatal in vivo binding of [3H]mazindol or [3H]cocaine in mice Neurosci Lett 205 1996 145 148
55. S.H. Dresel, M.P. Kung, K. Plossl, S.K. Meegalla, and H.F. Kung Pharmacological effects of dopaminergic drugs on in vivo binding of [99mTc]TRODAT-1 to the central dopamine transporters in rats Eur J Nucl Med 25 1998 31 39
56. M.M. de Win, J.B. Habraken, L. Reneman, W. van den Brink, G.J. den Heeten, and J. Booij Validation of [(123)I]beta-CIT SPECT to assess serotonin transporters in vivo in humans: a double-blind, placebo-controlled, crossover study with the selective serotonin reuptake inhibitor citalopram Neuropsychopharmacology 30 2005 996 1005
57. S.M. Meiergerd, T.A. Patterson, and J.O. Schenk D2 receptors may modulate the function of the striatal transporter for dopamine: kinetic evidence from studies in vitro and in vivo J Neurochem 61 1993 764 767
58. M. Batchelor, and J.O. Schenk Protein kinase A activity may kinetically upregulate the striatal transporter for dopamine J Neurosci 18 1998 10304 10309
59. I. Gordon, R. Weizman, and M. Rehavi Modulatory effect of agents active in presynaptic dopaminergic system on the striatal dopamine transporter Eur J Pharmacol 298 1996 27 30
60. C.A. Moody, J.G. Graneman, and M.J. Banon Dopamine transporter binding in rat striatum and nucleus accumbens is unaltered following chronic changes in dopamine levels Neurosci Lett 217 1996 55 57
61. M.G. Murer, G. Dziewczapolski, L.B. Menalled, M.C. Garcia, Y. Agid, and R. Raisman-Vozari Chronic levodopa is not toxic for remaining dopamine neurons, but instead promotes their recovery, in rats with moderate nigrostriatal lesions Ann Neurol 43 1998 561 575
62. 123I]FP-CIT binding in rat brain after acute and sub-chronic administration of dopaminergic medication Eur J Nucl Med 27 2000 346 349
63. K. Ikawa, A. Watanabe, S. Kaneno, and M. Toru Modulation of [3H]mazindol binding sites in rat striatum by dopaminergic agents Eur J Pharmacol 250 1993 261 266
64. L. Roiux, P.A. Frohna, J.N. Joyce, and J.S. Schneider The effects of chronic levodopa treatment on pre- and postsynaptic markers of dopaminergic function in striatum of parkinsonian monkeys Mov Disord 12 1997 148 158
65. K.K. Ganalingham, and R.G. Robertson The effects of chronic continuous versus intermittent levodopa treatments on striatal and extrastriatal D1 and D2 dopamine receptors and dopamine uptake sites in the 6-hydroxydopamine lesioned rat - an autoradiographic study Brain Res 640 1994 185 194
66. K.Y. Little, J. Gorebig, F.I. Caroll, J. Mapili, and J.H. Meador-Woodruff Lack of dopamine receptor agonists effect on striatal dopamine transporter binding sites Brain Res 742 1996 313 316
67. P. Allard, K. Eriksson, S.B. Ross, and J.O. Marcusson Unaltered [3H]GBR12935 binding after chronic treatment with dopamine active drugs Psychopharmacology 102 1990 291 294
68. 123I]beta-CIT Mov Disord 14 1999 436 442
69. E. Nurmi, J. Bergman, O. Eskola, O. Solin, S.M. Hinkka, P. Sonninen, and J.O. Rinne Reproducibility and effect of levodopa on dopamine transporter function measurements: a [18-F]CFT PET study J Cereb Blood Flow Metab 20 2000 1604 1609
70. J.E. Ahlskog, R.J. Uitti, M.K. O'Conor, D.M. Maraganore, J.Y. Matsumoto, K.F. Stark, M.F. Turk, and O.L. Burnett The effect of dopamine agonist therapy on dopamine transporter imaging in Parkinson's disease Mov Disord 14 1999 940 946
71. M. Guttman, D. Stewart, D. Hussey, A. Wilson, S. Houle, and S. Kish Influence of l-dopa and pramipexole on striatal dopamine transporter in early PD Neurology 56 2001 1559 1564
72. J.P. Seibyl, M. Laruelle, C.H. van Dyck, E. Wallace, R.M. Baldwin, S. Zoghbi, Y. Zea-Ponce, J.L. Neumeyer, D.S. Charney, P.B. Hoffer, and R.B. Innis Reproducibility of iodine-123-beta-CIT SPECT brain measurement of dopamine transporters J Nucl Med 37 1996 222 228
73. J.P. Seibyl, K.L. Marek, K. Shef, R.M. Baldwin, S. Zoghbi, Y. Zea-Ponce, D.S. Charney, C.H. van Dyck, P.B. Hoffer, and R.B. Innis Test/retest reproducibility of iodine-123-betaCIT SPECT brain measurements of dopamine transporters in Parkinson's patients J Nucl Med 38 1997 1453 1459
74. J. Booij, J.B.A. Habraken, P. Bergmans, G. Tissingh, A. Winogrodzka, E.C. Wolters, A.G. Janssen, J.C Stoof, and E.A. van Royen Imaging of dopamine transporters with iodine-123-FP-CIT SPECT in healthy controls and patients with Parkinson's disease J Nucl Med 39 1998 1879 1884